EEE

ELICERA THERAPEUTICS AB

No trades
See on Supercharts
Market capitalization
‪18.60 M‬SEK
−0.828SEK
‪−16.40 M‬SEK
‪8.41 M‬
Beta (1Y)
−0.04

About ELICERA THERAPEUTICS AB

CEO
Jamal El-Mosleh
Headquarters
Gothenburg
Employees (FY)
2
Founded
2014
FIGI
BBG01161YY50
Elicera Therapeutics AB operates as a clinical stage immuno-oncology company, which engages in the development of cell and gene therapies for immune-based cancer treatments. Its drug candidates are in the field of oncolytic viruses and in the field of cell therapies, in addition to a platform technology called iTANK (ImmunoTherapies Activated with Nap for efficient Killing) for further immune enhancement of treatments in said fields. Its product pipeline includes ELC-100, ELC-201, ELC-301, and ELC-401. The company was founded by Jamal El-Mosleh, Di Yu, and Magnus Essand in 2014 and is headquartered in Gothenburg, Sweden.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of ELIC is 0.950 SEK — it has increased by 1.06% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on OMXSTO exchange ELICERA THERAPEUTICS AB stocks are traded under the ticker ELIC.
ELIC stock is 13.74% volatile and has beta coefficient of −0.04. Check out the list of the most volatile stocks — is ELICERA THERAPEUTICS AB there?
Yes, you can track ELICERA THERAPEUTICS AB financials in yearly and quarterly reports right on TradingView.
ELIC stock has fallen by 22.45% compared to the previous week, the month change is a 36.88% fall, over the last year ELICERA THERAPEUTICS AB has showed a 74.04% decrease.
ELIC net income for the last quarter is ‪−4.75 M‬ SEK, while the quarter before that showed ‪−5.05 M‬ SEK of net income which accounts for 5.89% change. Track more ELICERA THERAPEUTICS AB financial stats to get the full picture.
No, ELIC doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, ELIC shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ELICERA THERAPEUTICS AB stock right from TradingView charts — choose your broker and connect to your account.
ELIC reached its all-time high on Aug 3, 2021 with the price of 9.000 SEK, and its all-time low was 0.900 SEK and was reached on Apr 25, 2024.
See other stocks reaching their highest and lowest prices.
As of Apr 27, 2024, the company has 2.00 employees. See our rating of the largest employees — is ELICERA THERAPEUTICS AB on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ELICERA THERAPEUTICS AB technincal analysis shows the sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ELICERA THERAPEUTICS AB stock shows the sell signal. See more of ELICERA THERAPEUTICS AB technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.